[Neuroendocrine tumours treated with mIBG and radiolabeled peptides].
Neuroendocrine tumours are a heterogeneous group, characterized by good prognosis, but important disparities of the evolutionary potential. In the aggressive forms, the therapeutic strategies are limited. The metabolic or systemic radiotherapy, using radiolabelled peptides, which can act at the same time on the primary tumour and its metastases, constitutes a tempting therapeutic alternative, currently in evolution. The preliminary results are encouraging; the prospects are related to the development of new radiopharmaceuticals, with the use of other peptide analogues whose applications will overflow the framework of the neuroendocrine tumours.
Giammarile
F
F
Département de Médecine Nucléaire, Centre Léon-Bérard, 28, rue Laennec, 69373 Lyon cedex 08, France. giammari@lyon.fnclcc.fr
Borson-Chazot
F
F
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D006801:Humans; D009447:Neuroblastoma / Q000188:drug therapy / Q000532:radiotherapy; D010235:Paraganglioma / Q000188:drug therapy / Q000532:radiotherapy; D010455:Peptides / Q000627:therapeutic use; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000627:therapeutic use
D000970:Antineoplastic Agents; D010455:Peptides; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine